Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies

IMPORTANCE: Many large adjuvant clinical trials end up underpowered because of fewer than expected events in the control arm. Ensuring a minimum number of events would result in more informative trials. OBJECTIVE: To calculate individualized residual risk estimates using residual risk prediction sof...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Oncol
Glavni autori: Wei, Wei, Kurita, Tomoko, Hess, Kenneth R., Sanft, Tara, Szekely, Borbala, Hatzis, Christos, Pusztai, Lajos
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2018
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885272/
https://ncbi.nlm.nih.gov/pubmed/29372234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5092
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items